Menu
Live News EQUITY L impact

DGX - Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease

Quest Diagnostics receives New York State approval for Haystack MRD, broadening patient access to ctDNA minimal residual disease testing

DGX

DGX - Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing